rare disease

Immedica to Acquire Biopharma Company Marinus

Stockholm, Sweden-headquartered global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals, a US commercial-stage pharmaceutical company developing therapies for seizure disorders, for enterprise value of approximately $151 million.

Pfizer Doubles Dublin Biologicals Capacity

Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.

After Pharma’s Patent Cliff